|
Jul 30
|
GSK’s speciality medicines soar while generals drop, Q2 results reveal
|
|
Jul 30
|
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
|
|
Jul 30
|
Glaxo: Q2 Earnings Snapshot
|
|
Jul 30
|
Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - OncoTherapy Science, Inovio, BioNTech, Theravectys, and GlaxoSmithKline
|
|
Jul 30
|
GSK Upbeat on Guidance After Specialty Medicines Boost Sales
|
|
Jul 28
|
Astrazeneca, Other US-Listed Pharma Companies Seen Insulated From New EU Tariff Deal, Barclays Says
|
|
Jul 28
|
Synthetic rescue: Insmed explores a new frontier in genetic therapeutics
|
|
Jul 28
|
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 24
|
Europe’s Pharma Stocks Look Cheap but Tariffs Cloud the Outlook
|
|
Jul 24
|
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
|
|
Jul 24
|
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
|
|
Jul 24
|
Is GSK plc's (LON:GSK) 27% ROE Better Than Average?
|
|
Jul 23
|
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
|
|
Jul 23
|
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Jul 23
|
Epilepsy Drugs Market Growth Analysis, Forecast Trends and Outlook Report 2025-2034 | Demand for Generic Epilepsy Drugs Rises as Patent Expirations Fuel Market Growth
|
|
Jul 21
|
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
|
|
Jul 21
|
Oral Care Market Analysis Report 2025-2032 | Emergence of Electric Toothbrushes, Introduction of Skincare-Inspired Oral Care Products, and Integration of AI in Toothbrushes
|
|
Jul 19
|
Warren Buffett says this book changed his life forever. Here's the real key to long-term gains
|
|
Jul 18
|
BofA Maintains a Sell Rating on GSK plc (GSK), Sets a PT of p1,510
|